Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

R. J. Firpi; T. T. Tran; P. Flores; N. Nissen; S. Colquhoun; C. Shackleton; P. Martin; J. M. Vierling; F. F. Poordad

doi:10.1111/j.1365-2036.2004.01923.x

Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

R. J. Firpi, T. T. Tran, P. Flores, N. Nissen, S. Colquhoun, C. Shackleton, P. Martin, J. M. Vierling, F. F. Poordad

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

Original language	English (US)
Pages (from-to)	1033-1039
Number of pages	7
Journal	Alimentary Pharmacology and Therapeutics
Volume	19
Issue number	9
DOIs	https://doi.org/10.1111/j.1365-2036.2004.01923.x
State	Published - May 1 2004
Externally published	Yes

ASJC Scopus subject areas

Hepatology
Gastroenterology
Pharmacology (medical)

Access to Document

10.1111/j.1365-2036.2004.01923.x

Cite this

@article{44033ac1ba584c72bc99b8955f6164f3,

title = "Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent",

abstract = "Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.",

author = "Firpi, {R. J.} and Tran, {T. T.} and P. Flores and N. Nissen and S. Colquhoun and C. Shackleton and P. Martin and Vierling, {J. M.} and Poordad, {F. F.}",

year = "2004",

month = may,

day = "1",

doi = "10.1111/j.1365-2036.2004.01923.x",

language = "English (US)",

volume = "19",

pages = "1033--1039",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

AU - Firpi, R. J.

AU - Tran, T. T.

AU - Flores, P.

AU - Nissen, N.

AU - Colquhoun, S.

AU - Shackleton, C.

AU - Martin, P.

AU - Vierling, J. M.

AU - Poordad, F. F.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

AB - Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

UR - http://www.scopus.com/inward/record.url?scp=2442695089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442695089&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2004.01923.x

DO - 10.1111/j.1365-2036.2004.01923.x

M3 - Article

C2 - 15113371

AN - SCOPUS:2442695089

SN - 0269-2813

VL - 19

SP - 1033

EP - 1039

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 9

ER -

Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this